HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lifeline Skin Care Grows Its Human Stem-Cell Anti-Aging Line

This article was originally published in The Rose Sheet

Executive Summary

Lifeline Skin Care expands its offerings with an eye treatment featuring its patented stem-cell extract. Exec Linda Nelson explained International Stem Cell Corporation’s technology and its applications for Lifeline at the recent SupplySide West conference.

You may also be interested in...

Stemology Anti-Aging Line Leverages Stem Cells From Humans, Plants

“Healing peptide” from adult human stem cells, plant stem cells and an intercellular communication enhancer make up the proprietary StemCore-3 technology in Dermatech Research’s Stemology skin-care line. Products in the collection range from $189 for Cell Revive Serum Complete to $19 for cleansing items.

FDA Warns Lancome For Gene/Stem-Cell Claims: A Signal To Marketplace?

L’Oreal/Lancome’s claims for Genifique anti-aging products, among others, identify the products as drugs under food and drug law, according to FDA’s Sept. 7 warning letter. Agency cites claims suggesting the brand’s technology “boosts the activity of genes” and “improve[s] the condition around the stem cells” – language that is not altogether unique in today’s anti-aging cosmeceutical market.

Lifeline For Aging Consumers: A Chat With International Stem Cell Corp's CEO

Oceanside, Calif.-based International Stem Cell Corporation recently announced that Lifeline Skin Care, an anti-aging range based on the biotechnology firm's parthenogenetic stem-cell technology, is available to the public through the brand's website following a soft debut in November.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts